Effect of P38mapk Inhibition on Receptor Activator of Nuclear Factor-Κb Ligand and Osteoprotegerin Expressions in Osteoblasts

李瑞霞,肖喜荣,顾超,徐嬿,李斌
DOI: https://doi.org/10.3969/j.issn.1672-8467.2010.01.009
2010-01-01
Abstract:Objective To investigate the role of p38MAPK in the differentiation of murine osteoblasts,and to observe the expressions of receptor activator of nuclear factor-κB ligand(RANKL) and osteoprotegerin(OPG). Methods The calvarial osteoblasts of newborn BALB/c mice were cultured in MEM medium containing 10% NCS.Raloxifene(10-7 mol/L) and 17β-estradiol(10-8 mol/L) were added respectively when cells reached 70%-80% confluence combined with or without 5 μmol/L SB202190,an inhibitor of p38MAPK.The osteoblasts alkaline phosphatase activity assays were performed 72 hours later using PNPP method,and mRNA levels of alkaliphosphatase(ALP),OPG and RANKL were determined by RT-PCR. Results 17β-estradiol and raloxifene increased ALP activity and ALP mRNA level in osteoblasts in vitro which were blocked by p38MAPK inhibitor.The mRNA levels of RANKL and OPG were up-regulated by 17β-estradiol and raloxifene while the ratio of OPG/RANKL kept constant.SB202190(5 μmol/L) inhibited the highly expressed RANKL and OPG in osteoblasts,and obviously decreased the ratio of OPG/RANKL. Conclusions p38MAPK inhibition blocked the differentiation of osteoblasts and decreased the up-regulated OPG and RANKL expressions in osteoblasts significantly(P0.05).
What problem does this paper attempt to address?